Truvada for profit, not patients

It is hard to overlook the medical strides that are responsible for saving lives and improving the quality of life for people infected with HIV. Despite notable progress, there is reason to believe that the drugs marketed to patients were not the safest and most effective drugs available at the time.

All fingers point to Gilead Sciences, Inc. to explain the gap between patient health and public knowledge. Gilead is the pharmaceutical manufacturer responsible for developing the so-called HIV "miracle drugs" containing tenofovir disoproxil fumarate (TDF). At the same time Gilead patented and marketed TDF drugs such as Viread and Truvada, they also created a better and safer drug called tenofovir alafenamide (TAF). Unlike TDF, TAF was designed to activate only after reaching HIV-infected cells. TAF fights the HIV virus more efficiently, working at a fraction of the dose and thereby eliminating the risk for serious bone and kidney injuries that resulted from compounded systemic exposure to toxic TDF drug compounds.

Rather than introducing the TAF to the market when it was ready, Gilead misrepresented the safety profile of TDF-based treatments for 15 years. Gilead went so far as to publicly discontinue the development of the TAF program, deceptively claiming that TAF did not differ enough from TDF to warrant further investigation. However, Gilead merely shelved their real miracle drug until their TDF patents expired, maximizing TDF-related profits all while positioning TAF for immediate success upon release.

Learn More About Your Legal Options

For nearly 20 years, Gilead dominated the HIV market at the expense of patient well-being. Unlike Gilead, Reich & Binstock is committed to putting clients, patients, and people first. If you believe that your bone or kidney injury is related to a TDF drug, Reich & Binstock can help you find out. Please call us in Houston at 713-352-7883 or 877-643-3099 toll free or complete our online form to find out more information about your rights.